BCM
DNLI icon

BlueCrest Capital Management’s Denali Therapeutics DNLI Stock Holding History

BlueCrest Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,571
Closed -$269K – 582
2019
Q1 		$269K Buy
+11,571
New +$242K 0.01% 768
2018
Q4 		– Sell
-14,900
Closed -$324K – 999
2018
Q3 		$324K Buy
+14,900
New +$246K 0.01% 996

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlueCrest Capital Management's DNLI Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Denali Therapeutics (DNLI) in Q2 2019, closing a stake of 11,571 shares — an estimated $269K sold.

BlueCrest Capital Management first reported a position in DNLI in Q3 2018 and held it in 2 quarters. The position peaked at $324K in Q3 2018. 114 funds tracked by Wall St. Rank hold DNLI as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Denali Therapeutics position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,571 Denali Therapeutics shares in Q2 2019, an estimated $269K.
  • BlueCrest Capital Management first reported a position in Denali Therapeutics in Q3 2018 and held it in 2 quarters.
  • BlueCrest Capital Management's Denali Therapeutics position peaked at $324K in Q3 2018.
  • 114 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.